VRDN Q4 2025 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$132,000+83.3% YoY

Gross Profit

-$188,000-142.4% margin

Operating Income

-$123M-92991.7% margin

Net Income

-$120M-91178.0% margin

EPS (Diluted)

$-1.11

QoQ Revenue Growth

-99.8%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$899M

Total Liabilities

$177M

Stockholders' Equity

$722M

Cash & Equivalents

$212M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$132,000	$72,000	+83.3%
Gross Profit	-$188,000	$72,000	-361.1%
Operating Income	-$123M	-$87M	-40.3%
Net Income	-$120M	-$80M	-51.0%

Revenue Segments

Collaboration

$279,000100%